Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ORKA is expected to report earnings to rise 8.40% to -59 cents per share on November 18
Q3'26
Est.
$-0.60
Q2'26
Missed
by $0.04
Q4'25
Beat
by $0.27
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.20
The last earnings report on August 10 showed earnings per share of -55 cents, missing the estimate of -50 cents. With 866.06K shares outstanding, the current market capitalization sits at 5.57B.